ATE502934T1 - Inhibitoren der wechselwirkung zwischen mdm2 und p53 - Google Patents

Inhibitoren der wechselwirkung zwischen mdm2 und p53

Info

Publication number
ATE502934T1
ATE502934T1 AT08804373T AT08804373T ATE502934T1 AT E502934 T1 ATE502934 T1 AT E502934T1 AT 08804373 T AT08804373 T AT 08804373T AT 08804373 T AT08804373 T AT 08804373T AT E502934 T1 ATE502934 T1 AT E502934T1
Authority
AT
Austria
Prior art keywords
mdm2
inhibitors
interaction
Prior art date
Application number
AT08804373T
Other languages
English (en)
Inventor
Virginie Sophie Poncelet
Sophie Coupa
Pierre-Henri Storck
Bruno Schoentjes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38910911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE502934(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE502934T1 publication Critical patent/ATE502934T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08804373T 2007-09-21 2008-09-18 Inhibitoren der wechselwirkung zwischen mdm2 und p53 ATE502934T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07116889 2007-09-21
PCT/EP2008/062433 WO2009037308A1 (en) 2007-09-21 2008-09-18 Inhibitors of the interaction between mdm2 and p53

Publications (1)

Publication Number Publication Date
ATE502934T1 true ATE502934T1 (de) 2011-04-15

Family

ID=38910911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08804373T ATE502934T1 (de) 2007-09-21 2008-09-18 Inhibitoren der wechselwirkung zwischen mdm2 und p53

Country Status (23)

Country Link
US (4) US9573933B2 (de)
EP (1) EP2203440B1 (de)
JP (1) JP5438007B2 (de)
CN (2) CN104761541A (de)
AR (1) AR068627A1 (de)
AT (1) ATE502934T1 (de)
AU (1) AU2008300527B2 (de)
BR (1) BRPI0817223B8 (de)
CA (1) CA2699849C (de)
CL (1) CL2008002798A1 (de)
DE (1) DE602008005784D1 (de)
DK (1) DK2203440T3 (de)
ES (1) ES2363838T3 (de)
HR (1) HRP20110394T1 (de)
JO (1) JO2704B1 (de)
MX (1) MX2010003060A (de)
PA (1) PA8796901A1 (de)
PE (1) PE20090817A1 (de)
RU (1) RU2477724C2 (de)
SI (1) SI2203440T1 (de)
TW (1) TWI434841B (de)
UY (1) UY31349A1 (de)
WO (1) WO2009037308A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
TWI476189B (zh) * 2009-02-04 2015-03-11 Janssen Pharmaceutica Nv 用作抗癌劑之吲哚衍生物
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
CN102321034B (zh) * 2011-06-07 2014-08-13 中国人民解放军第二军医大学 硫代苯二氮卓类化合物及其作为药物的用途
EP2771341A4 (de) * 2011-10-28 2015-09-23 Univ Texas Neue zusammensetzungen und verfahren zur behandlung von krebs
ES2410704B1 (es) * 2011-11-28 2014-04-29 Universitat De Barcelona Indoleninas fluoradas útiles para el tratamiento del cáncer.
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3558164B1 (de) 2016-12-21 2024-10-09 TriFlo Cardiovascular Inc. Herzklappenhaltevorrichtung und verfahren zur herstellung davon
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042224A1 (en) 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
DK1859798T3 (en) * 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
WO2003040402A2 (en) * 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
US7540139B2 (en) * 2004-08-16 2009-06-02 Rowse Hydraulic Rakes Co., Inc. Foldable hay rake
ATE474833T1 (de) * 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
US20060217370A1 (en) * 2005-02-18 2006-09-28 Ethan Burstein Compounds useful for the treatment and prevention of pain and screening methods therefor
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
ES2534899T3 (es) * 2007-08-06 2015-04-30 Janssen Pharmaceutica, N.V. Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53

Also Published As

Publication number Publication date
US9573933B2 (en) 2017-02-21
CN101868453A (zh) 2010-10-20
EP2203440B1 (de) 2011-03-23
BRPI0817223B1 (pt) 2020-04-07
US11583524B2 (en) 2023-02-21
SI2203440T1 (sl) 2011-07-29
RU2010115765A (ru) 2011-10-27
UY31349A1 (es) 2009-03-31
BRPI0817223B8 (pt) 2021-05-25
PA8796901A1 (es) 2009-05-15
DK2203440T3 (da) 2011-06-20
AU2008300527A1 (en) 2009-03-26
BRPI0817223A2 (pt) 2015-03-10
RU2477724C2 (ru) 2013-03-20
US20180263966A1 (en) 2018-09-20
CA2699849A1 (en) 2009-03-26
EP2203440A1 (de) 2010-07-07
TWI434841B (zh) 2014-04-21
HRP20110394T1 (hr) 2011-06-30
CA2699849C (en) 2015-10-27
JP2010539220A (ja) 2010-12-16
CL2008002798A1 (es) 2009-06-05
PE20090817A1 (es) 2009-07-02
ES2363838T3 (es) 2011-08-17
JO2704B1 (en) 2013-03-03
US20100240637A1 (en) 2010-09-23
AR068627A1 (es) 2009-11-25
MX2010003060A (es) 2010-04-07
TW200930709A (en) 2009-07-16
AU2008300527B2 (en) 2013-08-29
US20170112818A1 (en) 2017-04-27
DE602008005784D1 (de) 2011-05-05
WO2009037308A1 (en) 2009-03-26
JP5438007B2 (ja) 2014-03-12
CN104761541A (zh) 2015-07-08
US20200121667A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
ATE502934T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
ATE474833T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
EP2151440A4 (de) Heterocyclische verbindung und ihre verwendung
BRPI0814719A2 (pt) N-(2-(hetaril)aril)arilsulfonamidas e n-(2-(hetaril)arilsulfonamidas
EP2006278A4 (de) Benzofluorenverbindung und ihre verwendung
HRP20151052T1 (xx) Peteroäślani heterocikliäśki amidi i srodne tvari
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
HRP20150231T1 (xx) Kristalni oblik inhibitora međudjelovanja mdm2/4 i p53
ATE511509T1 (de) Azaindolylverbindungen und anwendungsverfahren
EP2094179A4 (de) Externe befestigungsanordnung und anwendungsverfahren
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
EP2383263A4 (de) Neues thiazolidindionderivat und dessen verwendung
DK2120604T3 (da) Fremgangsmåde til fraktionering af havre, produkter derved opnået, og anvendelser deraf
HRP20170222T1 (hr) Kristalni oblik karbamoil-cikloheksan derivata
FI20070973A0 (fi) Menetelmä pakkauksen muodostamiseksi ja pakkaus
BRPI0816789A2 (pt) Goji e inflamação
BRPI0908132A2 (pt) Composto de benzodiazepina e composição farmacêutica
EP2455380A4 (de) Heterocyclische verbindung und ihre verwendung
EP2121896A4 (de) Schwingungsflexibler und abgedichteter antrieb
DK2164572T3 (da) Carbamoyl-cyclohexaner til behandling af akut mani
ATE543500T1 (de) Kombinationen mit 5ht6-modulatoren und cholinesterase-hemmern
EP2399921A4 (de) Heterocyclische verbindung und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties